V8 Peptides — Engineered Performance
Research Library
TB-500: Actin-Binding Motif and Cell Migration Assays
TB-500Mechanism

TB-500: Actin-Binding Motif and Cell Migration Assays

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What is TB-500 and how is it studied in cell migration assays? On the V8 product page, TB-500 is the synthetic 17–23 fragment of thymosin β4, the N-acetylated heptapeptide Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ), about 889 Da, molecular formula C38H68N10O14, supplied as a 10 mg lyophilized vial at ≥98% HPLC purity. The LKKTET stretch is the region of full-length thymosin β4 that binds monomeric actin, so the fragment is used in actin-regulation, cell-migration and angiogenesis models. Published work on whole thymosin β4 reported effects on keratinocyte and endothelial migration; whether the short fragment reproduces them has to be tested in each assay, which is why controls matter. For laboratory research use only.

TB-500 is a name that covers more than one thing in casual use, and the difference changes experimental design. This article concentrates on the bench: which assays are used to ask about actin and migration, what each can show, and which controls keep the fragment from being credited with results that belong to the 43-residue parent protein. Background and structure are covered further in the TB-500 research overview and the comparison TB-500 vs thymosin beta-4. Everything here concerns in vitro and preclinical laboratory work; the compound is for laboratory research use only and not for human consumption.

The actin-binding motif

Thymosin β4 is a 43-amino-acid peptide present at high concentration in many cell types and a principal G-actin-sequestering molecule. Reviews by Goldstein, Hannappel and Kleinman (2005) describe how it holds actin monomers in a pool that is not available for polymerization and how that role links it to cell motility and tissue repair. Sanders, Goldstein and Wang (1992) showed in living cells that it regulates actin polymerization. The actin-binding site was mapped to a central stretch containing the sequence LKKTET, which is the core of the fragment sold as TB-500.

Seen as a design, the heptapeptide keeps the part of the parent that binds actin and drops everything else. The N-terminal acetyl cap mirrors the acetylated N-terminus of the native protein and removes a charged amine. The consequences are straightforward:

  • The fragment is small enough to be fully synthetic with high purity, and it has no disulfides and no methionine or tryptophan to oxidize.
  • It has three acidic or polar residues and two lysines, so its net charge near neutral pH is close to zero to slightly positive.
  • Functions of the parent that depend on regions outside residues 17–23 are not expected to carry over automatically.
FeatureThymosin β4 (43 residues)TB-500 as listed (Ac-LKKTETQ)
Length43 residues7 residues
Actin-binding motifPresent (LKKTET core)Present
N-terminusAcetylatedAcetylated
MassAbout 4.96 kDaAbout 889 Da
Assay-ready featuresLarge, many charged residuesSmall; no tryptophan or tyrosine, so weak absorbance at 280 nm
Evidence baseExtensive cell and animal literatureMostly inferred from parent; direct data are limited

The last row is the one to remember. The primary literature cited throughout this article concerns thymosin β4 itself. Claims about the fragment should be made only when the fragment has been tested.

What the thymosin β4 literature reported

Several of the best-known papers describe parent-protein experiments, and they define the readouts that a fragment study would borrow.

  • Keratinocyte migration and wound models. Malinda and colleagues (1999) reported that thymosin β4 stimulated keratinocyte migration in a Boyden chamber assay and increased re-epithelialization in a rat full-thickness wound model after topical or intraperitoneal administration.
  • Angiogenesis and wound repair. Philp, Goldstein and Kleinman (2004) summarize reports that thymosin β4 promoted endothelial cell migration, angiogenesis and hair follicle development in animal systems.
  • Cardiac cell migration. Bock-Marquette and colleagues (2004) reported that thymosin β4 activated integrin-linked kinase and promoted cardiac cell migration and survival in mouse models.
  • Corneal models. Sosne and colleagues (2001) reported effects on corneal wound closure and inflammatory mediators in mice.

These are descriptions of what the authors found in specific species and systems. They are not statements about the heptapeptide and are not recommendations.

Assays that probe actin and migration

AssayWhat it measuresStrengthWeakness
Pyrene-actin polymerizationRate of actin assembly in vitroDirect test of actin interaction with purified componentsCell-free; says nothing about uptake or signaling
Scratch (wound-closure) assayCollective migration of a monolayerSimple, quantitative with time-lapseProliferation confounds closure unless blocked
Boyden or transwell chamberDirected migration through a porous membraneUsed in the keratinocyte work cited above; good for concentration-range findingEndpoint assay; membrane coating affects results
Endothelial tube formationNetwork formation on basement membrane matrixQuick angiogenesis screenSensitive to matrix lot and cell passage
Phalloidin imagingF-actin organization and lamellipodiaShows the cytoskeleton directlyQualitative unless quantified carefully
Cell survival or viabilityMetabolic activity or membrane integrityControls for toxicity or growth effectsDoes not report on migration

Controls that keep the interpretation honest

  1. Full-length thymosin β4 arm, if available, to show whether the fragment behaves like the parent in the same system.
  2. Scrambled heptapeptide with the same composition and acetylation, to separate sequence-specific effects from non-specific peptide effects.
  3. Motif mutant in which lysines or glutamate in the LKKTET core are substituted, to test whether actin binding is required.
  4. Proliferation block such as mitomycin C or low-serum medium in scratch assays, so that closure reflects migration.
  5. Vehicle matched for diluent, preservative and pH.
  6. Concentration range rather than a single point, because migratory responses to actin-binding agents are often biphasic.

An experiment designed this way can support one of three conclusions: the fragment mimics the parent, the fragment is inactive, or the fragment behaves differently. All three are informative. A design without these arms can support none of them.

Interpreting actin data

Actin readouts are easy to over-read. In a pyrene assay, a sequestering agent lowers the rate and extent of polymerization by reducing the free monomer pool, so a slower curve is the expected result for an actin-binding peptide and does not by itself indicate activity in cells. In cells, the free G-actin pool is already buffered by endogenous thymosin β4 and profilin, so adding a small peptide from outside may change little unless it enters the cell or acts at the surface. This is a reason to pair any phenotypic assay with a measurement of the intracellular F-actin to G-actin ratio, for example by fractionation and immunoblot, and to ask whether the fragment reaches the cytoplasm at all. Labeled analogs and uptake controls answer that question more directly than a migration curve can.

It also helps to keep the related literature in view. The BPC-157 research overview describes a peptide whose reported migration effects are attributed to different signaling, which is why combinations are designed with separate single-agent arms, as discussed in BPC-157 and TB-500 combination research.

Documentation for repeatable migration work

  • Lot number, purity and certificate status; whether the powder was white and loose or otherwise.
  • Diluent, stock concentration (vial mass ÷ diluent volume), aliquot number and freeze–thaw count.
  • Cell line, passage, serum percentage and matrix coating.
  • Assay duration, imaging interval and the analysis method used to quantify closure or migrated cells.
  • Controls run in the same plate or the same week as the test arms.

Handling the heptapeptide

The TB-500 product page lists lyophilized powder in a sealed clear glass research vial, with storage at 2–8 °C, −20 °C for long-term holding and protection from heat, moisture and light. Short peptides with no cysteine, methionine or tryptophan are among the more stable, so the main risks are microbial growth after reconstitution, loss through adsorption and repeated freeze–thaw. Manning and colleagues (2010) review solution-state instability, and Goebel-Stengel and colleagues (2011) describe the choice of plasticware for peptides. Practical points:

  • Let the sealed vial reach room temperature before opening to avoid condensation.
  • Add diluent slowly along the wall and swirl; shaking is unnecessary for a soluble heptapeptide and creates foam.
  • Divide into single-use aliquots; thaw once.
  • Use low-binding tubes, particularly for the dilute working solutions used in migration assays.
  • Check the stock for clarity and color each time it is used and record the observation.

Concentration equals vial mass divided by diluent volume; the reconstitution calculator carries out the arithmetic. For procedure see how to reconstitute a lyophilized peptide; for purity data and certificate fields, TB-500 purity testing and the COA library. Combination work with other repair-pathway peptides is covered in BPC-157 vs TB-500, and further products are in the shop.

Limits of the evidence

Three limits are worth stating. The strongest data concern the full protein, not the fragment. Wound and migration models are sensitive to species, strain, wound geometry and the vehicle used. And migration in a dish is a cell behavior that does not translate automatically to tissue-level outcomes. The compound is supplied for laboratory research use only, and nothing in this article is a recommendation for use in people or animals.

Frequently asked questions

What is TB-500 according to the product page?

A synthetic 17–23 fragment of thymosin β4, Ac-LKKTETQ, about 889 Da, formula C38H68N10O14, supplied as a 10 mg lyophilized vial with ≥98% HPLC purity.

Is TB-500 the same as thymosin β4?

No. Thymosin β4 has 43 residues. TB-500 as listed is a seven-residue fragment containing the actin-binding LKKTET motif.

Which part of thymosin β4 binds actin?

A central stretch containing the sequence LKKTET, which is the core of the fragment.

Do thymosin β4 results apply to the fragment?

Not automatically. The cited primary papers studied the full protein, so effects of the fragment must be shown in its own assays.

Which assays suit an actin-binding fragment?

Pyrene-actin polymerization for direct interaction, plus scratch, transwell, tube-formation and phalloidin imaging in cells, with a viability readout alongside.

Why include a scrambled peptide?

It has the same composition but a different order, which separates sequence-specific effects from general peptide effects.

Why block proliferation in scratch assays?

Wound closure can reflect dividing cells rather than migrating cells. Mitomycin C or low-serum medium isolates migration.

What species and routes did the wound studies use?

Malinda and colleagues reported a rat full-thickness wound model with topical or intraperitoneal administration of thymosin β4, and a Boyden chamber assay for keratinocyte migration.

How is the sealed vial stored?

The product page states 2–8 °C, with −20 °C for the long term, protected from heat, moisture and light.

Is TB-500 sold for use in people or animals?

No. It is supplied for laboratory research use only and is not for human or animal consumption.

Related reading: TB-500 and Thymosin β4 Wound Healing Animal Studies, How to Reconstitute TB-500: A Laboratory Guide, TB-500 Preclinical Studies: Fragment vs Thymosin Beta-4.

References

  1. Sanders MC, Goldstein AL, Wang YL. Thymosin beta 4 (Fx peptide) is a potent regulator of actin polymerization in living cells. Proc Natl Acad Sci USA. 1992;89(10):4678-4682. doi:10.1073/pnas.89.10.4678
  2. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. doi:10.1016/j.molmed.2005.07.004
  3. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. doi:10.1046/j.1523-1747.1999.00708.x
  4. Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. doi:10.1016/j.mad.2003.11.005
  5. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. doi:10.1038/nature03000
  6. Sosne G, Chan CC, Thai K, et al. Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo. Exp Eye Res. 2001;72(5):605-608. doi:10.1006/exer.2000.0985
  7. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
  8. Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.